HIF-1α protein expression is associated with the environmental inflammatory reaction in Barrett's metaplasia

Diseases of the Esophagus

Volumn 22, Issue 8, 2009, Pages 694-699

  Ling, F C ^a   Khochfar, J ^a   Baldus, S E ^a   Brabender, J ^a   Drebber, U ^b   Bollschweiler, E ^a   Hoelscher, A H ^a   Schneider, P M ^a,c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; HIF 1a protein expression; Hypoxia; Inflammation.

Indexed keywords

HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADENOCARCINOMA; AGED; ARTICLE; BARRETT ESOPHAGUS; DISEASE COURSE; ESOPHAGUS; ESOPHAGUS TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PHYSIOLOGY; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; RETROSPECTIVE STUDIES;

EID: 77649328304     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.00957.x     Document Type: Article

References (25)

1. Reid B J. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 1991; 20: 817-34.
2. Spechler S J, Goyal R J. The columnar-lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996; 110: 614-21.
3. Vaninetti N M, Geldenhuys L, Porter G A et al. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinog 2008; 47: 275-85.
4. Moons L M G, Kusters J G, van Delft J H M et al. A proinflammatory genotype predisposes to Barrett's esophagus. Carcinogenesis 2008; 29: 926-31.
5. Risques R A, Vaughan T L, Li X et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007; 16: 2649-55.
6. Semenza G L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
7. Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors-causes and consequences. Am J Physiol Regul Integr Comp Physiol 2004; 286: R608-23.
8. Kurokawa T, Miyamoto M, Kato K et al. Overexpression of hypoxia-inducible-factor 1α (HIF-1α) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 2003; 89: 1042-7.
9. Sohda M, Ishikawa H, Masuda N et al. Pretreatment evaluation of combined HIF-1α, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 2004; 110: 838-44.
10. Matsuyama T, Nakanishi K, Hayashi T et al. Expression of hypoxia-inducible factor-1a in esophageal squamous cell carcinoma. Cancer Sci 2005; 96: 176-82.
11. Griffiths E A, Pritchard S A, McGrath S M et al. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer 2007; 96: 1377-83.
12. Schlemper R J, Riddell R H, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
13. Faller G, Borchard F, Ell C et al. Histopathological diagnosis of Barrett's mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Arch 2003; 443: 597-601.
14. Xi H, Baldus S E, Warnecke-Eberz U et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005; 11: 8341-7.
15. Dixon M F, Genta R M, Yardley J H, Correa P, and participants in the International Workshop on the Histopathology of Gastritis, Houston 1994. Classification and grading of gastritis. The Updated Sydney System. Am J Surg Pathol 1996; 20: 1161-81.
16. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Stat Assoc 1937; 32: 675-701.
17. Friedman M. A comparison of alternative tests of significance for the problem of m rankings. Ann Math Stat 1940; 11: 86-92.
18. Cramer T, Yamanishi Y, Clausen B E et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003; 112: 645-57.
19. Janssen H L, Haustermans K M, Sprong D et al. HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002; 54: 1537-49.
20. Sandau K B, Fandrey J, Brüne B. Accumulation of HIF-1α under the influence of nitric oxide. Blood 2001; 97: 1009-15.
21. Thomas D D, Espey M G, Ridnour L A et al. Hypoxic inducible factor 1a, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. PNAS 2004; 101: 8894-9.
22. McMahon S, Charbonneau M, Grandmont S, Richard D E, Dubois C M. Transforming growth factor β1 induces hypoxiainducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281: 24171-81.
23. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 2004; 40: 1660-7.
24. Jung Y J, Isaacs J S, Lee S, Trepel J, Neckers L. IL-1b mediated up-regulation of HIF-1α via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17: 2115-7.
25. Lopez-Lazaro M. Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2006; 15: 2332-5.